About Us

CMIC and Lokavant Collaborate to Utilize Clinical Trial Intelligence Platform

Artificial Intelligence (AI) , Machine Learning (ML), Natural Language Processing (NLP), Deep Learning (DL), AI Model, AI-powered Solutions, Digital Transformation, ML Model, Natural Language Understanding (NLU), AI News, Artificial Intelligence News
A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

A leading Japanese Contract Research Organization (CRO) CMIC, announced that they have teamed with a leading clinical trial intelligence company, Lokavant, to deploy a clinical trial intelligence platform driven by machine learning (ML).

Through this strategic partnership, both the companies will utilize its analytics platform for monitoring and management of clinical trials mostly in the Asia Pacific region. Also Lokavant’s monitoring and operational risk management platform, Lokavant Oversight, will be available all over across CMIC studies. The following agreement between CMIC and Lokavant showcases that this is the first of its kind predictive analytics partnership for clinical trial operations in the APAC market.

Yoshihito Kondo, Executive Vice President of Clinical Operation at CMIC, shared his excitement, “We are thrilled to be more proactive in study management and expand our global footprint by entering into this agreement to partner with Lokavant. This strategic relationship, centered around Lokavant’s deep data science and predictive capabilities in trial execution, will ensure that CMIC continues to be a leader with a focus on technology and innovation.”

The partnership between CMIC and Lokavant leaves behind all the traditional risk-based monitoring through its end-to-end solution driven by Lokavant’s historical operational data and CMIC’s data. CMIC can operate next-generation risk-based monitoring to predict data quality issues, study timeline delays, and budget overruns. CMIC clinical teams will use historical data to predict future issues so that the teams can be proactive in reducing issues and delivering better trial outcomes. Lokavant and CMIC will also co-develop data-driven metrics to monitor study performance of all the historical and ongoing CMIC studies.

Rohit Nambisan, President of Lokavant, said, “Lokavant is excited to deploy our machine learning-driven applications, which will enable CMIC to predict and address trial risk. CMIC’s leading clinical development expertise and scale make them a great partner for Lokavant, and together we are excited to shift the paradigm in clinical trial operations in APAC, the US, and globally.”

Recent News